The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis

David Alexandre (1) , Coralie Hautot (1) , Marwa Mehio , Lydie Jeandel (1) , Maïte Courel (2) , Thierry Voisin (3) , Alain Couvineau (4) , Françoise Gobet (5) , Jérôme Leprince (6, 1, 7) , Christian Pfister (8) , Youssef Anouar (1) , Nicolas Chartrel (7)

1 DC2N - Différenciation et communication neuronale et neuroendocrine
2 LBD-E14 - Compartimentation et trafic intracellulaire des mRNP = Compartmentation and intracellular traffic of mRNPs
3 CRI (UMR_S_1149 / ERL_8252 / U1149) - Centre de recherche sur l'Inflammation
4 U1149, Centre de recherche sur l'inflamation (CRI)
5 Service d'Anatomie et Cytologie Pathologique [CHU Rouen]
6 Neuroendocrinologie cellulaire et moléculaire
7 DC2N - Différenciation et communication neuronale et neuroendocrine
8 Service d'urologie [Rouen]

In the present study, we have examined the presence of orexins and their receptors in prostate cancer (CaP) and investigated their effects on the apoptosis of prostate cancer cells.

Keywords: Apoptosis; Cancer; G protein-coupled receptor; Neuroendocrine differentiation; Neuropeptide; Proliferation; Prostate cancer therapy

Domains: Chemical Sciences; Medicinal Chemistry; Life Sciences [q-bio]; Cellular Biology; Cell Behavior [q-bio.CB]; Life Sciences [q-bio]; Neurons and Cognition [q-bio.NC]; Neurobiology; Life Sciences [q-bio]; Pharmaceutical sciences; Pharmacology

David Alexandre, Coralie Hautot, Marwa Mehio, Lydie Jeandel, Maïte Courel, et al.. The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis. European Journal of Cancer, 2014, 50 (12), pp.2126-2133. ⟨10.1016/j.ejca.2014.05.008⟩. ⟨hal-01960616⟩